Loading
Lung Cancer Treatments and Mutations / HER2/EGFR in Cancer Research · Journal article
Proceedings of the National Academy of Sciences · August 10, 2026
Raises a question worth testing. It does not answer one.
This mechanistic study demonstrates that multiple receptor tyrosine kinase (RTK) fusions suppress epidermal growth factor receptor (EGFR) signaling through Grb2 sequestration in cultured cancer cells, and that kinase inhibition releases this suppression and potentiates EGFR-driven survival signals. The work proposes a signaling principle and identifies a potential therapeutic opportunity but provides no direct evidence of clinical benefit or in vivo efficacy.
Cell-based mechanistic study using live- and fixed-cell microscopy in isogenic and patient-derived cell lines. Cultured cancer cell lines: isogenic cell lines and patient-derived cell lines expressing various RTK fusion oncoproteins, with emphasis on EML4-ALK.. Intervention: Targeted kinase inhibitors against RTK fusions; synthetic optogenetic fusion analogs. Compared with: Untreated or control cell lines; cells expressing optogenetic constructs without fusion signaling capability.
A wide variety of RTK fusions suppress transmembrane EGFR signaling via Grb2 sequestration mechanism RTK fusions are found in ~5% of all cancers collectively Targeted therapy against fusion kinases rapidly released Grb2 from sequestration and potentiated EGFR activity
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work identifies a mechanistic principle that could inform rational drug combination strategies—co-targeting fusion kinases with EGFR inhibition—but clinical validation and in vivo proof-of-concept are required before practice recommendations can be made. The findings suggest that single-agent kinase inhibitor resistance may partly reflect EGFR-driven survival escape.
Mechanistic cell-based study establishing a signaling principle in cancer cells; proposes a model for RTK fusion behavior but lacks clinical outcome data or in vivo validation needed to guide practice.
As stated by the source record.
Quoted from the source exactly as published.
This work identifies a mechanistic principle that could inform rational drug combination strategies—co-targeting fusion kinases with EGFR inhibition—but clinical validation and in vivo proof-of-concept are required before practice recommendations can be made. The findings suggest that single-agent kinase inhibitor resistance may partly reflect EGFR-driven survival escape.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Regulation of cancer cells by their environment contributes to tumorigenesis and drug response, though the extent to which the oncogenic state can alter a cell’s perception of its environment is not clear. EML4-ALK is a receptor tyrosine kinase (RTK) fusion oncoprotein that suppresses transmembrane EGFR signaling in cancer cells. ALK inhibition restores signaling through EGFR, thereby promoting survival and drug tolerance. Here, we tested whether such modulation of EGFR activity was common among other RTK fusions, which collectively are found in ~5% of all cancers. Using live- and fixed-cell microscopy in isogenic and patient-derived cell lines, we found that a wide variety of RTK fusions suppress transmembrane EGFR, through mechanisms that include the sequestration of the adaptor protein Grb2. Targeted therapies rapidly released Grb2 from sequestration and potentiated EGFR. Synthetic optogenetic analogs of RTK fusions confirmed that cytoplasmic sequestration of Grb2 was sufficient to suppress perception of extracellular EGF and could do so without driving signaling from the synthetic fusion itself, demonstrating that fusion signaling and suppression of EGFR signaling could be functionally decoupled. Our study uncovers that a large number of RTK fusions simultaneously act as both activators and suppressors of signaling, the mechanisms of which could be exploited for biomimetic therapies that enhance cell killing and suppress drug tolerance.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.